• Explore /
  • Poster
  • / Weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).

Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).

Abstract Poster

Authors

null

Denise A. Yardley

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

Denise A. Yardley , Javier Cortes , Robert E. Coleman , Pier Franco Conte , Adam Brufsky , Joyce O'Shaughnessy , Gail Lynn Shaw Wright , Janice F. Eakle , Sharon Wilks , Mikhail Shtivelband , Robyn R. Young , Carmelo Bengala , Huiling Li , Julie Ann Miller , Debora Barton , Nadia Harbeck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT01881230

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS1106)

DOI

10.1200/jco.2015.33.15_suppl.tps1106

Abstract #

TPS1106

Poster Bd #

217a

Abstract Disclosures

Similar Posters

First Author: Denise A. Yardley

First Author: Sudeep Gupta

First Author: Leisha A. Emens

First Author: Moshe J. Inbar